Related Experiment Video

Updated: May 1, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on: October 17, 2025

1.1K

Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations

Sarah Guenounou1, Eric Delabesse, Christian Récher

  • 1Service d'Hématologie, Centre Hospitalier Universitaire de Toulouse, Hôpital Purpan, Toulouse, France.

European Journal of Haematology
|April 3, 2014
PubMed

Insights

This study shows that combining sorafenib and all-trans retinoic acid (ATRA) can effectively treat acute myeloid leukemia (AML) with specific NPM1 and FLT3-ITD mutations.

Area of Science:

  • Hematology
  • Oncology
  • Molecular Biology

Background:

  • Acute myeloid leukemia (AML) research is advancing, focusing on targeted therapies for molecular defects.
  • NPM1 and FLT3-ITD mutations occur in 20% of cytogenetically normal AML.
  • Sorafenib (FLT3 inhibitor) and all-trans retinoic acid (ATRA) show promise for AML treatment.

Observation:

  • Three patients with refractory or relapsed FLT3-ITD(+) /NPM1(+) AML were treated.
  • The combination therapy included sorafenib and ATRA.

Findings:

  • All three patients achieved a significant response to the sorafenib and ATRA combination therapy.
  • This suggests a potent therapeutic effect for this specific AML subtype.

Implications:

  • The combination of sorafenib and ATRA may represent a new therapeutic strategy for FLT3-ITD(+) /NPM1(+) AML.
  • Further clinical trials are warranted to validate these findings.
  • This approach could improve outcomes for patients with this challenging AML subset.
Keywords:
Acute myeloid leukemiaFLT3-ITD mutationNPM1 mutationall trans retinoid acidsorafenibtargeted therapy

More Related Videos

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues07:17

Author Spotlight: Advancing the Detection of Low-Frequency Mutations in Cancer Tissues

Published on: August 23, 2024

1.8K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

26.1K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.6K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K